Neurogene (NASDAQ:NGNE) Coverage Initiated by Analysts at SVB Leerink

SVB Leerink initiated coverage on shares of Neurogene (NASDAQ:NGNE) in a report published on Monday, MarketBeat reports. The brokerage issued an outperform rating and a $46.00 price target on the stock.

Several other equities research analysts have also issued reports on the company. HC Wainwright raised their price objective on Neurogene from $45.00 to $55.00 and gave the company a buy rating in a research note on Tuesday, March 19th. Stifel Nicolaus assumed coverage on Neurogene in a research report on Friday, January 5th. They issued a buy rating and a $31.00 price target for the company. TD Cowen began coverage on shares of Neurogene in a research report on Thursday, January 4th. They set an outperform rating on the stock. Finally, William Blair began coverage on shares of Neurogene in a research note on Thursday, March 21st. They issued an outperform rating and a $61.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Neurogene has a consensus rating of Buy and an average price target of $48.25.

Neurogene Stock Up 11.5 %

Shares of NASDAQ:NGNE opened at $33.40 on Monday. The business has a fifty day simple moving average of $37.91. The stock has a market cap of $429.19 million, a PE ratio of -2.68 and a beta of 1.26. Neurogene has a 52 week low of $12.20 and a 52 week high of $53.00.

Institutional Trading of Neurogene

A number of hedge funds and other institutional investors have recently bought and sold shares of NGNE. Great Point Partners LLC bought a new position in shares of Neurogene in the fourth quarter worth about $19,268,000. Avidity Partners Management LP purchased a new stake in Neurogene in the 4th quarter valued at about $9,036,000. BML Capital Management LLC bought a new position in Neurogene in the 4th quarter worth about $478,000. Finally, Privium Fund Management UK Ltd purchased a new position in shares of Neurogene during the first quarter worth approximately $274,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.